This is a first look at on! PLUS Mint 6mg, based on manufacturer specifications and FDA filings — I have not used the product, so there are no scores on this page. on! PLUS is Helix Innovations’ second-generation pouch line, authorised by the FDA in six versions (Mint, Tobacco and Wintergreen, at 6 mg and 9 mg). The 6 mg Mint sits at the top of what most American pouch users would call the middle of the range, in an unusually large 0.714 g pouch.
Why this is a first look and not a review
Every scored review on this site comes from a product I have actually had in my lip. I have not had this one, so rather than pad a page with adjectives I cannot stand behind, I have written up what is knowable: what Helix filed with the FDA, what the FDA said when it authorised the line, and what the published numbers do and do not tell you. When I get a can, this page gets scores and a flavour assessment.
That is more useful than it sounds, because on! PLUS is better documented than most pouches. FDA’s technical review of the application is public, and it contains a pouch weight — the single hardest number to find in this category.
What on! PLUS actually is
on! PLUS is made by Helix Innovations LLC, an Altria operating company, and it is a separate line from the older on! mini pouches rather than a replacement for them. The two lines do not overlap on strength at all: FDA has authorised on! at 2 mg and 4 mg (Autumn Spice, Cappuccino and Rich Berry), and on! PLUS at 6 mg and 9 mg (Mint, Tobacco and Wintergreen). If you have used on! before and are picking up on! PLUS expecting the same thing in a new wrapper, you are jumping at least two steps up.
Altria describes the line as featuring “our proprietary NICOSILK™ technology and a built-in compartment for responsible disposal”. NICOSILK is described only qualitatively as a soft-feel pouch material, with no specification anywhere in the public record, so I would treat it as marketing language until someone measures something. The disposal compartment in the lid is a real piece of design, and the kind of thing that only matters once you have carried a used pouch around in a pocket.
The FDA technical review is blunter about what is inside: the products are “pouched oral tobacco products containing tobacco-derived nicotine, flavor ingredients, artificial sweeteners, stabilizers, fillers, and pH adjusters”, and they “are not smokeless tobacco products as they do not consist of cut, ground, powdered, or leaf tobacco”. Note tobacco-derived. There is no tobacco leaf in the pouch, but the nicotine is extracted from tobacco rather than synthesised — which is why FDA regulates it as a tobacco product and why the word people reach for, “tobacco-free”, is only true of the leaf.
What the FDA authorisation does and does not say
This is the part that gets mangled in retail copy, so it is worth quoting exactly. FDA’s Center for Tobacco Products announcement says: “Today, FDA authorized the marketing of 6 nicotine pouch products through the premarket tobacco product application (PMTA) pathway.” FDA’s marketing-orders table records the order date as 19 December 2025; the announcement page carries a January 2026 timestamp, and Altria’s own account puts the authorisation in December 2025. These were the first decisions out of the nicotine-pouch review pilot FDA launched in September 2025.
FDA’s findings, in its own words, were that the products “contain lower levels of most harmful and potentially harmful constituents (HPHCs) when compared to other oral and smokeless tobacco products”, “do not contain measurable levels of several carcinogenic HPHCs, including those shown to be important drivers of excess oral cancer risk”, and “have the potential to provide a benefit to adults who smoke cigarettes and/or use other smokeless tobacco products”.
And then, in the same document: “While today’s actions permit these specific nicotine pouch products to be legally marketed in the U.S. to adults 21 and older, it does not mean these tobacco products are safe, nor are they ‘FDA approved.’ … There is no safe tobacco product.”
One more distinction that matters. A marketing authorisation is not a modified-risk order. ZYN holds a modified-risk order, granted 30 June 2026, permitting a specific comparative claim about substituting for cigarettes. on! PLUS does not. Anything you read implying on! PLUS is authorised as lower-risk is reading a PMTA order as if it were an MRTP order, and those are different filings against different legal standards.
The specs, and the holes in them
Helix’s application, as summarised in FDA’s technical review, gives a portion weight target of 0.714 g, portion dimensions of 27.5 mm by 10.5 mm, and 14 pouches per can. That is a genuinely large pouch by pouch standards — the German federal risk institute BfR found a median pouch weight of 0.6 g across 44 products on the German market, and Finland has since legislated a 0.5–1.0 g band. A 0.714 g pouch will feel like more material under the lip than a slim ZYN, and 14 per can is two fewer than the 15-count and 20-count formats common elsewhere.
What is missing is more interesting. The nicotine-per-gram figure, the pH and the moisture content are all redacted from the public review as confidential commercial information. So the only honest way to state the concentration is to do the arithmetic yourself: 6 mg in a 0.714 g pouch is about 8.4 mg/g. That is my division, not a published figure, and it is worth knowing that the ZYN review from the same agency in the same period has its portion weight redacted too — so you cannot even run the same sum on the obvious comparison.
The pH matters more than the missing mg/g, because pH is what determines how much of the nicotine is in the free-base form that crosses the mucosa quickly. BfR measured a median pH of 8.8 and a median free-base fraction of 86% across the pouches it examined, with the free-base share varying enormously between products. Without on! PLUS’s pH, the 6 mg on the can tells you about content and very little about the experience.
What 6 mg actually means
The figure on the can is nicotine content, not delivered dose, and the gap is large. BfR concluded that “at least half of the nicotine in the pouch can be absorbed”, and the extraction figures it reproduces for pouches run around 50–59%. Independent measurement has found the gap can be wider: in a 2024 study in Frontiers in Pharmacology, pouches declared at 6 mg measured 4.8 mg of actual content and delivered a mean extracted dose of 1.8 mg.
Nobody has published an independent measurement of on! PLUS specifically. I looked. There is a 2026 Raman-spectroscopy paper on on!-brand pouches, but I could not obtain the full text or confirm whether the PLUS line was among the samples, so I report no numbers from it.
What the specs suggest, and what they don’t
What looks good on paper: the FDA authorisation is real and specific, and the HPHC findings behind it are the most rigorous public assessment any pouch on the US market has been through. The disposal compartment is a sensible bit of engineering. The pouch weight is published, which is more than its main competitor manages. And the 6/9 mg pairing is a coherent ladder for someone who has outgrown 4 mg.
What I would want to check: 0.714 g is a lot of pouch, and bulk is the most common reason people abandon a product they otherwise like. The 14-count can is worse value per tin than a 15 or 20. Three flavours is a thin range next to ZYN’s ten. And with pH withheld, the 6 mg number is close to uninterpretable — a 6 mg pouch at pH 9 and a 6 mg pouch at pH 7 are not the same product in any way that matters.
Specifications
| Specification | on! PLUS Mint 6mg | Source |
|---|---|---|
| Manufacturer | Helix Innovations LLC (Altria) | FDA technical review |
| Nicotine per pouch | 6 mg (product designation) | FDA; Altria |
| Portion weight | 0.714 g target | FDA technical review |
| Portion dimensions | 27.5 mm × 10.5 mm target | FDA technical review |
| Pouches per can | 14 | FDA technical review |
| Nicotine per gram | Not published (redacted); ≈8.4 mg/g by my arithmetic | — |
| pH / free-base fraction | Not published (redacted) | — |
| Moisture | Not published (redacted) | — |
| Nicotine source | Tobacco-derived | FDA technical review |
| Flavours in line | Mint, Tobacco, Wintergreen | FDA; Altria |
| Strengths in line | 6 mg, 9 mg | FDA; Altria |
| FDA status | PMTA marketing granted order; no modified-risk order | FDA |
| US retail | Nationwide from 23 March 2026 | Altria |
Who this looks right for
On the documentation alone, this reads as a product for an adult who already uses nicotine, has found 2–4 mg pouches unsatisfying, and wants something that has been through a full FDA premarket review. The large pouch points the same way.
I would not point a first-time pouch user at 6 mg in a 0.714 g format, and I would not point anyone at it who does not already use nicotine. If you are sensitive to bulk under the lip, try one can before buying a roll — and if flavour range matters to you, three options will not be enough.
Alternatives worth reading about first
ZYN at 6 mg is the obvious comparison, and the only line carrying a modified-risk order. If 6 mg is a step up you are unsure about, the complete mg guide explains why the number on the can is a poor guide to strength, and the master ranking collects everything that has actually been scored.
Sources
- FDA, Center for Tobacco Products, FDA authorizes 6 nicotine pouch products, completing review in record time.
- FDA, Technical Project Lead review of nicotine pouch PMTAs, Helix Innovations LLC (redacted) — portion weight, dimensions, per-can count, ingredients.
- FDA, Nicotine pouch products authorized by the FDA.
- FDA, FDA authorizes 20 ZYN nicotine pouches to be marketed with a specific modified risk claim, 30 June 2026.
- Altria Group, on! PLUS expands nationwide retail availability, 23 March 2026.
- Bundesinstitut für Risikobewertung, Health risk assessment of nicotine pouches, updated BfR opinion 023/2022, 7 October 2022 — pouch weight, pH, free-base fraction, extraction.
- Mallock-Ohnesorg N. et al., Small pouches, but high nicotine doses, Frontiers in Pharmacology, 2024 — measured content versus label, extracted dose.